Please login to the form below

Not currently logged in
Email:
Password:

Olumiant

This page shows the latest Olumiant news and features for those working in and with pharma, biotech and healthcare.

NICE publishes draft guidance recommending three COVID-19 treatments

NICE publishes draft guidance recommending three COVID-19 treatments

The treatments recommended by NICE are Roche’s RoActemra (tocilizumab) and Eli Lilly’s Olumiant (baricitinib), both indicated for use in a hospitalised setting in patients requiring supplemental oxygen, as well

Latest news

More from news
Approximately 10 fully matching, plus 36 partially matching documents found.

Latest Intelligence

  • NICE – but not enough NICE – but not enough

    Olumiant launched in 2017 and received positive recommendations from NICE and SMC in the middle of Q3 that same year. ... Today – more than three years after its NICE TA – Olumiant is finally approaching full implementation.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Lilly’s already-approved Olumiant (baricitinib) and Pfizer’s PF-04965842 are rivals for Abbvie’s upadacitinib, but Gilead and Galapagos’ filgotinib (an AbbVie cast-off) now looks like the biggest

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement
How does Pharma-HCP engagement need to evolve in today's digital landscape?...